Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled dose-ranging study of ARA 290 in sarcoidosis-associated neuropathy
NL-OMON23963Phase 2Not yet recruiting
- Sponsor
- Araim Pharmaceuticals
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cibinetide in sarcoidosis and small fiber neuropathy (SFN) (4 arms), sponsored by Araim Pharmaceuticals. Primary endpoint: Change in corneal nerve fiber density. Planned start Jan 2014; status: not yet recruiting.
02
Drugs
cibinetide
03
Conditions
sarcoidosissmall fiber neuropathy (SFN)
Beyond the preview
Go deeper on NL-OMON23963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23963.